Clinical characteristics and risk factors of late-stage lung adenocarcinoma patients with bacterial pulmonary infection and its relationship with cellular immune function DOI Creative Commons
Kangli Yang,

Haiting Wei,

Weiwei Zhu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 16, 2025

To research the clinical characteristics, risk factors, correlation between bacterial pulmonary infection and immune function of advanced lung adenocarcinoma patients complicated with infection. 334 stage III IV admitted to first affiliated hospital Zhengzhou University from January 2020 March 2023 were selected divided into an group (n = 240) a control (n= 72) according whether The characteristics analyzed. microbiota human T lymphocyte subsets (CD3+, CD4+, CD8+) detected. Multivariate logistic regression analysis was performed explore factors for in patients. Among patients, 264 cases infection, 70 had no In total, 544 pathogenic bacteria isolated Of these, 170 strains (31.25%) Gram-negative bacilli, 162 (29.78%) Gram-positive cocci, 27 (4.96%) bacilli. There statistically significant differences age, smoking, combined diseases, TNM staging, CD3+ cell percentage, CD4+ percentage two groups (P < 0.05). revealed bronchiectasis, diabetes independent leading late-stage those on checkpoint inhibitors, has higher number cells CD4+/CD8+ ratio than Smoking, are adenocarcinoma. effect inhibitor treatment is more pronounced Gram positive bacteria.

Language: Английский

Immune checkpoint blockade in experimental bacterial infections DOI Creative Commons
Nicole Lind Henriksen, Peter Østrup Jensen, Louise Kruse Jensen

et al.

Journal of Infection, Journal Year: 2025, Volume and Issue: unknown, P. 106391 - 106391

Published: Jan. 1, 2025

Highlights•Immune checkpoint blockade can reduce the bacterial burden of various infections•The efficacy immune in infections is pathogen dependent•Further research essential for clinical translation blockadeAbstractImmune inhibitors designed to reinvigorate responses suppressed by cancer cells have revolutionized therapy. Similarities dysregulation between and infectious diseases has prompted investigations into role checkpoints diseases, including therapeutic potential drug repurposing. While most centered around viral infections, data are emerging. This systematic review reports on vivo effect selected preclinical studies infection, aiming assess if there could be a rationale using immunotherapy infections. Of 42 analyzed studies, reduced 60% had no 28% increased 12%. Findings suggest that context-dependent part relates pathogen. Further required understand how mediated different used as an adjuvant conventional infection management strategies.

Language: Английский

Citations

1
Emerging antimicrobial therapies for Gram-negative infections in human clinical use DOI Creative Commons
S Hickson, Emma L. Ledger, Timothy J. Wells

et al.

npj Antimicrobials and Resistance, Journal Year: 2025, Volume and Issue: 3(1)

Published: Feb. 27, 2025

The growing problem of multi-drug resistance (MDR) is prevalent in Gram-negative infections, and the significant decline antibiotic development poses a critical threat to global public health. Many emerging non-antibiotic therapies have been proposed, including phage therapy, anti-virulence agents, antimicrobial peptides, plasmapheresis, immunotherapy options. To identify most likely be next immediate step treatment for MDR this review highlights therapeutics that either successfully used compassionate care or are currently undergoing clinical trials.

Language: Английский

Citations

1
Clinical characteristics and risk factors of late-stage lung adenocarcinoma patients with bacterial pulmonary infection and its relationship with cellular immune function DOI Creative Commons
Kangli Yang,

Haiting Wei,

Weiwei Zhu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 16, 2025

To research the clinical characteristics, risk factors, correlation between bacterial pulmonary infection and immune function of advanced lung adenocarcinoma patients complicated with infection. 334 stage III IV admitted to first affiliated hospital Zhengzhou University from January 2020 March 2023 were selected divided into an group (n = 240) a control (n= 72) according whether The characteristics analyzed. microbiota human T lymphocyte subsets (CD3+, CD4+, CD8+) detected. Multivariate logistic regression analysis was performed explore factors for in patients. Among patients, 264 cases infection, 70 had no In total, 544 pathogenic bacteria isolated Of these, 170 strains (31.25%) Gram-negative bacilli, 162 (29.78%) Gram-positive cocci, 27 (4.96%) bacilli. There statistically significant differences age, smoking, combined diseases, TNM staging, CD3+ cell percentage, CD4+ percentage two groups (P < 0.05). revealed bronchiectasis, diabetes independent leading late-stage those on checkpoint inhibitors, has higher number cells CD4+/CD8+ ratio than Smoking, are adenocarcinoma. effect inhibitor treatment is more pronounced Gram positive bacteria.

Language: Английский

Citations

0